Yonsei University Health System, Severance Hospital
Welcome,         Profile    Billing    Logout  
 446 Trials 
826 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shin, Dong M
NCT03840291: Resolution of Thrombi in Left Atrial Appendage With Edoxaban

Completed
4
36
RoW
Edoxaban, Lixiana®
Keimyung University Dongsan Medical Center, Daiichi Sankyo Korea Co., Ltd., a Daiichi Sankyo Company
Atrial Fibrillation, Left Atrial Appendage Thrombosis
10/23
08/24
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

Active, not recruiting
3
291
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer
05/23
02/26
RODIN, NCT05041010: Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz

Recruiting
3
496
RoW
Neu2000KWL group, Placebo group
GNT Pharma
Ischemic Stroke
06/24
01/25
NCT03200340: EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation

Completed
2
105
US
EC-18, EC-18 soft capsules, Placebo, Placebo capsule
Enzychem Lifesciences Corporation
Stomatitis
05/21
05/21
EA3163, NCT03493425: Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

Recruiting
2
82
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Image Guided Radiation Therapy, IGRT, image-guided radiation therapy, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Questionnaire Administration, Therapeutic Conventional Surgery
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7
03/29
03/29
SB-SCI-001, NCT04812431: Safety and Exploratory Efficacy of Transplantation Therapy Using PSA-NCAM(+) NPC in AIS-A Level of Sub-acute SCI

Recruiting
1/2
5
RoW
Neural precursor cells derived from human embryonic stem cell line
S.Biomedics Co., Ltd., Linical Co., Ltd., Yonsei University
Spinal Cord Injury, Acute, Spinal Cord Injury at C4 Level With Complete Lesion, Spinal Cord Injury at C5-C7 Level With Complete Lesion
10/28
09/30
BEAT, NCT03590730: Benefits of ICD for the Primary Prevention in Patients With Valvular Cardiomyopathy

Terminated
N/A
12
RoW
ICD implantation
Keimyung University Dongsan Medical Center, Medtronic
Valvular Heart Disease, Implantable Cardioverter Defibrillator, Sudden Cardiac Death, Primary Prevention
07/19
07/21
NCT03932604: Atrial Sensing Capability for Better Detection of Atrial Fibrillation

Recruiting
N/A
640
RoW
Atrial sensing On mode
Samsung Medical Center, Biotronik SE & Co. KG
Implantable Cardioverter Defibrillator, Atrial Fibrillation, Cardiac Event, Cardiac Arrhythmia
12/21
05/23
NCT05078918: Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors

Recruiting
N/A
800
RoW
Comprehensive care program, Education and re-evaluation process, Usual care, Providing usual care
Samsung Medical Center, Ministry of Science and ICT, Korea
Lung Cancer, Lung Neoplasm
09/24
02/25
Kim, Yong Sik
NCT04803266: Elective Internal Mammary Node Irradiation in Women With Node-positive Breast Cancer

Active, not recruiting
3
747
RoW
Internal mammary node irradiation, No internal mammary node irradiation
Yonsei University
Breast Neoplasms
02/23
02/23
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Recruiting
3
510
Europe, Canada, Japan, US, RoW
LY3650150, Placebo, Standard therapy for INCS
Eli Lilly and Company
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
10/26
02/27
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
GLORIOSA, NCT05445778: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer

Recruiting
3
418
Europe, Canada, US, RoW
Mirvetuximab soravtansine plus Bevacizumab, MIRV, Bevacizumab
AbbVie, GOG Foundation
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
03/27
04/29
NCT06677944: Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer

Recruiting
2
47
RoW
Preoperative PBI
Yonsei University
Breast Cancer, Ductal Carcinoma in Situ, Invasive Breast Cancer
10/25
10/26
BBT877-IPF-004, NCT05483907: To Evaluate the Efficacy, Safety, and Tolerability of BBT-877 in Patients with IPF

Hourglass Jul 2023 - Dec 2023 : Interim data for the treatment of IPF
Checkmark Initiation of trial in idiopathic pulmonary fibrosis
Nov 2022 - Nov 2022: Initiation of trial in idiopathic pulmonary fibrosis
Active, not recruiting
2
129
Europe, US, RoW
BBT-877, Placebo
Bridge Biotherapeutics, Inc.
Idiopathic Pulmonary Fibrosis
01/25
09/25
NCT06207474: A Study on BReast Cancer Patient Care Using chAtbot and Video Education for Radiation Therapy (BRAVE)

Completed
N/A
148
RoW
Video + Chatbot, Video + Paper, Paper + Chatbot, Paper + Paper
Yonsei University
Breast Neoplasms
04/23
04/23
3STLIF, NCT04823858: 3Spine Lumbar Fusion Real World Evidence Study

Recruiting
N/A
200
US
Lumbar Interbody Fusion
3Spine, MCRA
Lumbar Spine Degeneration
05/24
08/26
SDM-ADOPT, NCT06618638: Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment

Recruiting
N/A
340
RoW
Shared decision making model, Usual Care
Seoul National University Hospital, Seoul National University, Hallym University Kangnam Sacred Heart Hospital, Kangbuk Samsung Hospital, Korea University Guro Hospital, Seoul National University Boramae Hospital, Asan Medical Center, InjeUniversityBusanPaikHospital, Chonnam National University Hospital, Keimyung University Dongsan Medical Center
ADPKD (autosomal Dominant Polycystic Kidney Disease)
09/26
09/26
TLIF, NCT04073563: Transforaminal Lumbar Interbody Fusion

Recruiting
N/A
1017
US, RoW
Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems
Medtronic Spinal and Biologics
Degenerative Disease of the Lumbosacral Spine
04/26
04/28
SABR-ROC, NCT05444270: Salvage Systemic Therapy With or Without Stereotactic Ablative Radiotherapy for Recurrent Ovarian Cancer

Recruiting
N/A
270
RoW
Standard salvage therapy, Standard salvage therapy + SABR
Yonsei University
Recurrent Epithelial Ovarian Cancer
12/26
12/26
K-BIO, NCT03929887: KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis

Recruiting
N/A
3000
RoW
Kidney Biopsy
Seoul National University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, KangWon National University Hospital, Keimyung University Dongsan Medical Center, SMG-SNU Boramae Medical Center, Seoul National University Bundang Hospital, Severance Hospital, Ministry of Health & Welfare, Korea
Glomerular Disease, Minimal Change Disease, IgA Nephropathy, Membranous Nephropathy, Focal Segmental Glomerulosclerosis, Lupus Nephritis, Crescentic Glomerulonephritis
12/28
12/28
Rha, Sun Young
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
eNRGy, NCT02912949 / 2014-003277-42: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion

Active, not recruiting
2
250
Europe, Canada, Japan, US, RoW
zenocutuzumab (MCLA-128), bispecific, MCLA-128
Merus N.V.
Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion
12/26
12/26
NCT05512182: Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Withdrawn
2
50
RoW
Chemotherapy
Yonsei University
Recurrent/Advanced Gastric Cancer
10/23
10/23
NCT05270889: Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial

Not yet recruiting
2
50
RoW
Tislelizumab+Zanidatamab
Yonsei University
HER2-positive Gastric Cancer
06/24
06/24
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
07/25
07/25
HER-RAM, NCT04888663: Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer ( Study)

Active, not recruiting
1/2
50
RoW
Trastuzumab + Ramucirumab + Paclitaxel
Yonsei University
Recurrent/Metastatic Gastric Cancer
09/21
09/21
NCT05400915: Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients

Completed
1/2
27
RoW
Variltinib, Paclitaxel
Yonsei University
Gastric Cancer
12/21
06/22
NCT05529667: Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

Completed
1/2
15
RoW
INCB054828, Paclitaxel
Yonsei University
Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel
08/23
08/23
NCT04592211: Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer

Recruiting
1/2
71
RoW
olaparib+pembrolizumab+paclitaxel
Yonsei University
Gastric Cancer Stage IV
12/24
05/25
YH32367-101, NCT05523947: Clinical Trial of YH32367 in Patients with HER2 Positive Locally Advanced or Metastatic Solid Tumor

Recruiting
1/2
137
RoW
YH32367
Yuhan Corporation
HER2-Positive Solid Tumor
10/26
12/26
NCT04835896: Study of M7824 and Paclitaxel Combination as a Second-line Treatment in Patients With Recurrent/Metastatic Gastric Cancer

Completed
1/2
49
RoW
M7824+paclitaxel
Yonsei University
Recurrent/Metastatic Gastric Cancer
10/23
10/23
NCT05894824: T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Recruiting
1/2
58
RoW
T-Dxd(Trastuzmab deruxtecan), Ramucirumab, Enhertu, Cyramza
Yonsei University
Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer
05/25
01/26
NCT05508737: Pembrolizumab and Trifluridine/Tipiracil With Previously Treated Advanced Gastric Cancer

Active, not recruiting
1/2
75
RoW
Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®), Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)
Yonsei University
Gastric and Gastroesophageal Junction Adenocarcinoma
05/25
12/25
NCT03821233: A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Completed
1
112
Canada, US, RoW
ZW49
Zymeworks BC Inc.
HER2-expressing Cancers
09/24
10/24
KEYNOTE-C16, NCT04374877: Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Recruiting
1
260
US, RoW
CHS-388, Casdozokitug, Pembrolizumab, Keytruda®, Toripalimab, Loqtorzi®
Coherus Biosciences, Inc., Merck Sharp & Dohme LLC
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
12/25
08/26
NCT05159440: First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer

Active, not recruiting
1
70
US, RoW
TORL-2-307-MAB
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
12/24
12/25
NCT05156866: First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Recruiting
1
70
US, RoW
TORL-2-307-ADC
TORL Biotherapeutics, LLC, Translational Research in Oncology
Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
01/25
01/26
NCT02951091: Biomarker-Integrated Umbrella, Advanced Gastric Cancer

Completed
N/A
400
RoW
biomarker screening
Yonsei University
Gastric Cancer
12/21
03/24
Zolbetuximab, NCT06767449: Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer

Recruiting
N/A
80
RoW
Yonsei University
Advanced Gastric Cancer
12/26
12/26
Kim, Min Chan
NCT05664555: Dose Optimization for Safe and Efficient Fluorescein Angiography (DOSE Study)

Completed
4
144
RoW
Fluorescein Sodium
Seoul National University Bundang Hospital
Retinal Disease
03/24
03/24
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
NRG-GY019, NCT04095364: Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recruiting
3
450
Europe, Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Imaging Technique, Diagnostic Imaging Technique, Image Type, Imaging, Imaging (procedure), imaging procedure, Imaging Procedures, imaging type, IMAGING_METHOD, imaging_type, Medical Imaging, Type of imaging, Letrozole, CGS 20267, Femara, Fempro, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat
NRG Oncology, National Cancer Institute (NCI)
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
02/27
02/28
CRESCENDO, NCT06072131: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL

Recruiting
3
504
Europe, US, RoW
Belinostat Injection, Beleodaq®, Pralatrexate Injection, Folotyn®, CHOP, Cyclophosphamide, Hydroxydaunorubicin (doxorubicin), Oncovin (vincristine), and Prednisone, COP, Cyclophosphamide, Oncovin (vincristine), and Prednisone
Acrotech Biopharma Inc.
Peripheral T Cell Lymphoma
07/30
11/30
NCT04696120: Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial

Not yet recruiting
2
200
RoW
Apixaban, apixaban 5mg or 2.5mg bid, Placebo, placebo bid
Korea University Guro Hospital, Dt&Sanomedics
Heart Failure, Sinus Rhythm, Cerebrovascular Disease
08/22
02/23
NCT05665023: Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma

Recruiting
2
37
RoW
Bevacizumab + modified FOLFIRINOX
Yonsei University
Mucinous Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
02/24
02/25
SRF388-201, NCT05359861: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Active, not recruiting
2
134
US, RoW
SRF388, Atezolizumab, Tecentriq, Bevacizumab, Avastin, Placebo
Coherus Biosciences, Inc.
Hepatocellular Carcinoma
05/25
05/26
NCT04903873: A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors

Recruiting
1/2
110
US, RoW
EU101
Eutilex
Solid Tumor, Renal Cell Cancer Metastatic, Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Prostate Cancer
09/25
12/25
BOLD-100-001, NCT04421820 / 2022-003079-41: BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours

Recruiting
1/2
220
Europe, Canada, US, RoW
BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion), BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)
Bold Therapeutics, Inc., Bold Therapeutics, Inc. (Bold)
Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
06/26
09/26
NCT05113693: Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393

Completed
1
33
RoW
CKD-393, CKD-501, D759, H053
Chong Kun Dang Pharmaceutical
Type 2 Diabetes
12/21
12/21
NCT05113849: Study to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine (IN-B009) in Healthy Adults (COVID-19)

Recruiting
1
40
RoW
IN-B009 (Low-dose), IN-B009 (High-dose)
HK inno.N Corporation
COVID-19
02/23
02/23
EARLY-UNLOAD, NCT04775472: Early Left Atrial Septostomy Versus Conventional Approach After Venoarterial Extracorporeal Membrane Oxygenation

Completed
N/A
116
RoW
Early left atrial septostomy within 12 hours after VA-ECMO implantation, Selective left atrial septostomy
Chonnam National University Hospital
Cardiogenic Shock
03/22
10/23
PLOTS, NCT04066699: Percutaneous Localization: Open-label Registry of Thoracic Surgery

Completed
N/A
70
US
Percutaneous localization of suspicious lung lesion(s) using electromagnetic navigation and tools., SPiN Thoracic Navigation System™, Veran System
Veran Medical Technologies
Lung Lesion(s) Requiring Evaluation, Pulmonary Metastasis, Pulmonary Nodule, Solitary, Peripheral Lung Lesions
01/23
02/23
VISION, NCT04151615: VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma

Completed
N/A
203
RoW
Boryung Pharmaceutical Co., Ltd
Multiple Myeloma
01/23
01/23
NCT04853563: Comparison of PEEP in Acute Decompensated Heart Failure

Recruiting
N/A
120
RoW
PEEP
Asan Medical Center
Heart Decompensation, Mechanical Ventilation Pressure High
07/23
04/24
NCT03763604: Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Approved for marketing
N/A
Europe, Canada, RoW
Abemaciclib, LY2835219
Eli Lilly and Company
Metastatic Breast Cancer
 
 
NCT05629611: Efficacy and Safety Evaluation of Vi-sealer

Recruiting
N/A
280
RoW
Vi-Sealer, Ligasure, Other AHD
Hyun Park
Benign Gynecologic Neoplasm
12/24
10/25
NCT04322851: B-line by Lung US in Patients With Acute Decompensated Heart Failure

Recruiting
N/A
300
RoW
Lung ultrasound
Asan Medical Center
Heart Failure
03/24
03/24
FRAME-AMI3, NCT06227754: OCT Versus Angiography for Culprit Lesion Revascularization in Acute Myocardial Infarction PatiEnts

Recruiting
N/A
1500
RoW
Angiography-guided PCI group, Optical coherence tomography-guided PCI group
Chonnam National University Hospital, Samsung Medical Center
ST Elevation Myocardial Infarction, Myocardial Infarction
12/28
12/29
ORIGO, NCT06597175: Evaluating Investigational Medical Device for Breast Tumor Diagnosis Using Diffusion Optical Spectroscopy

Recruiting
N/A
300
RoW
ORIGO
Olive Healthcare
Breast Cancer, Breast Tumor, Mammary Carcinoma, Human
10/24
10/24
NCT06537752: A Study to Evaluate Ethanol-induced Symptoms and Safety in Breast Cancer Patients

Recruiting
N/A
1052
RoW
Boryung Pharmaceutical Co., Ltd
Breast Cancer
10/26
10/26
EARLY-HF, NCT04810806: Timing of Coronary Angiography in NSTE-ACS With ADHF

Terminated
N/A
316
RoW
Immediate coronary angiography within 2 hours after randomization, Delayed coronary angiography after stabilization of heart failure
Chonnam National University Hospital
Heart Failure, Acute Coronary Syndrome
03/24
03/24
NCT04968808: Timing of FFR-guided PCI for Non-IRA in NSTEMI and MVD (OPTION-NSTEMI)

Recruiting
N/A
676
RoW
Staged in-hospital complete revascularization, Immediate complete revascularization
Chonnam National University Hospital
Myocardial Infarction, Acute, Multi-Vessel Coronary Artery Stenosis, Multi Vessel Coronary Artery Disease
08/24
08/25
NCT05493904: PREcise Percutaneous Coronary Intervention for Stent OptimizatION in Treatment of COMPLEX Lesion (PRECISION-COMPLEX)

Recruiting
N/A
320
RoW
OCT-guided PCI, Angiography-guided PCI, Drug-eluting stent
Chonnam National University Hospital, Abbott Medical Devices
Coronary Artery Disease, Angina Pectoris
08/24
12/26
NCT06049914: Combined Exercise and Nutrition Intervention for Possible Sarcopenia Among Older Adults in Primary Care

Recruiting
N/A
94
RoW
Experimental group
Kyunghee University Medical Center
Sarcopenia
12/24
12/24
MAeSTroⅡ-SDM, NCT06730893: Shared Decision-Making for Determining Treatment Strategies in Low-Risk Thyroid Cancer

Not yet recruiting
N/A
294
NA
share decision aids
National Cancer Center, Korea, Seoul National University Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Nowon Eulji Medical Center, Hanyang University
Thyroid Cancer, Papillary Thyroid Carcinoma
12/27
12/27
OPTION-STEMI, NCT04626882: Timing of FFR-guided PCI for Non-IRA in STEMI and MVD

Active, not recruiting
N/A
994
RoW
Staged in-hospital or Immediate complete revascularization
Chonnam National University Hospital
Myocardial Infarction, Acute, Multi-Vessel Coronary Artery Stenosis
02/25
12/29
NCT05276258: Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients

Enrolling by invitation
N/A
75
US
cryoSPHERE Ablation, cryoSPHERE, Bupivacaine, liposomal bupivacaine, Exparel
The Methodist Hospital Research Institute
Pain, Pain, Postoperative
03/25
09/25
NCT05585411: PReventive Effect Of Left Bundle Branch Area Pacing Versus righT vEntricular paCing on All Cause deaTh, Heart Failure Progression, and Ventricular dysSYNChrony in Patients With Substantial Ventricular Pacing (PROTECT-SYNC): Multicenter Prospective Randomized Controlled Trial

Recruiting
N/A
450
RoW
Left bundle branch area pacing, Right ventricular pacing
Yonsei University
Bradyarrhythmia, Atrioventricular Block, Left Bundle Branch Area Pacing
11/26
11/26
PACE-SHOCK, NCT06078436: Pulmonary Artery Catheterization and Carvedilol Early Initiation in Cardiogenic SHOCK Due to HFrEF

Recruiting
N/A
160
RoW
Pulmonary artery catheter, Swan-Ganz catheter
Min-Seok Kim
Heart Failure With Reduced Ejection Fraction, Cardiogenic Shock
09/27
03/28
RETHINK REFLUX, NCT04253392: Registry

Active, not recruiting
N/A
500
Europe, US, RoW
LINX Reflux Management System, LINX
Ethicon Endo-Surgery
Gastroesophageal Reflux
07/32
07/32
SOROCk, NCT04251052: A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Recruiting
N/A
2262
Canada, US, RoW
Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, bilateral salpingo-oophorectomy, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, transvaginal sonography, TVS, TVU, Ultrasound Imaging, 2-Dimensional Grayscale Ultrasound Imaging, 2-Dimensional Ultrasound Imaging, 2D-US, Ultrasonography, Ultrasound, Ultrasound Test, Ultrasound, Medical, US
NRG Oncology, National Cancer Institute (NCI)
Ovarian Carcinoma
06/36
06/37
NCT04174157: Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Recruiting
N/A
700
Europe, Japan, US, RoW
Prospective observational registry, Zolgensma
Novartis Pharmaceuticals, United BioSource, LLC
Spinal Muscular Atrophy (SMA)
06/38
06/38
KOBOT, NCT02803970: KOrean Borderline Ovarian Tumor () Registry

Recruiting
N/A
3000
RoW
Kangbuk Samsung Hospital
Ovarian Neoplasms
12/40
12/40
NCT04999072: Carbohydrate Antigen 19-9 in Colorectal Cancer

Active, not recruiting
N/A
4972
RoW
Colectomy for colon cancer
Seoul National University Hospital
Colorectal Cancer
09/21
12/21
Hyung, Woo Jin
NCT02995850: A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis

Completed
1/2
25
RoW
CRS+HIPEC
Yonsei University
Gastric Cancer With Peritoneal Metastasis (PCI<12)
04/22
05/22
NCT03385018: Trial for Application of Laparoscopic Total Gastrectomy With Lymph Node Dissection for Gastric Cancer (KLASS-06)

Recruiting
N/A
772
RoW
Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by laparoscopic approach, Radical total gastrectomy with D2 (D2 - #10) lymph node dissection by open conventional approach
Yonsei University
Gastric Cancer
12/22
12/27
NCT01919242: Postoperative Morbidity and Mortality After Gastrectomy for Gastric Cancer: Prospective Cohort Study

Recruiting
N/A
10000
RoW
gastrectomy
Yonsei University
Patients Who Underwent Gastrectomy With Lymph Node Dissection for Gastric Cancer
09/23
09/23
Ahn, Joong B
NCT04810585: Plasma Biomarker for Aflibercept in Advanced Colorectal Cancer

Recruiting
4
153
RoW
Aflibercept + FOLFIRI
Yonsei University
Recurrent or Metastatic Colorectal Cancer
10/25
10/25
MATINEE, NCT04133909 / 2018-001540-56: Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level

Jan 2024 - Dec 2024: Acceptance of regulatory submission in US (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in EU (based on MATINEE trial) for COPD
Jan 2024 - Dec 2024: Data from MATINEE trial for COPD
Jan 2024 - Dec 2024: Acceptance of regulatory submission in China (based on MATINEE trial) for COPD
Hourglass Jul 2024 - Dec 2024 : Regulatory decision in Japan for COPD
Completed
3
806
Europe, Canada, US, RoW
Placebo, Mepolizumab
GlaxoSmithKline, PPD DEVELOPMENT, LP
Pulmonary Disease, Chronic Obstructive
08/24
08/24
NCT05103020: Phase II Study Comparing Conversion Rate to Surgery With Hepatic Arterial Infusion Chemotherapy to Systemic Chemotherapy in Patients With Non Resectable Liver-only Colorectal Metastases

Recruiting
2
100
RoW
intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks, IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks
Yonsei University
Metastatic Colorectal Cancer
03/23
03/25
NCT03641976: A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastatic Right-sided Colon Cancer

Recruiting
2
120
RoW
A-FOLFOXIRI, Arm II (A-FOLFOX/A-FOLFIRI)
Yonsei University
Unresectable Metastatic Right-sided Colon Cancer Starting First-line Combination Chemotherapy, Unresectable Metastatic Right-sided Colon Cancer, Stage IV
06/24
06/24
TANGO, NCT06029595: Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy

Recruiting
2
464
Europe, RoW
Experimental: CHF6001 3200 μg, Placebo Comparator: CHF6001 Placebo
Chiesi Farmaceutici S.p.A.
Uncontrolled Asthma
12/25
12/25
NCT03286738: Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer

Recruiting
N/A
1800
RoW
FOLFIRI, target agent
Joong Bae Ahn
Metastatic Colorectal Cancer
12/21
12/21
Lim, Sun
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
CHAMELEON, NCT06020989: Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy

Not yet recruiting
2
129
RoW
Lazertinib+Pemetrexed+Carboplatin, Lazertinib
Yonsei University
Non Small Cell Lung Cancer
09/24
12/25
NCT05167851: The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Not yet recruiting
2
68
RoW
Lazertinib , a combination group of SBRT, Lazertinib single administration group
Yonsei University
Non Small Cell Lung Cancer
12/25
12/25
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, Nelistotug, GSK4381562
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
05/27
05/27
TRX-221-001, NCT06186076: A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC Patients

Recruiting
1/2
115
RoW
TRX-221
Therapex Co., Ltd
Carcinoma, Non-Small-Cell Lung, EGFR Mutant Advanced Non-Small Cell Lung Cancer
06/27
06/28
NCT05394831: A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

Recruiting
1/2
150
US, RoW
JIN-A02
J Ints Bio
EGFR Mutant Advanced Non-small Cell Lung Cancer
07/24
11/25
NCT04536428: ClearEndoclip Versus EZ Clip for Upper Gastrointestinal Ulcer Bleeding

Active, not recruiting
N/A
176
RoW
Endoscopic hemostasis with clip
Ajou University School of Medicine, Keimyung University Dongsan Medical Center, Korea University Anam Hospital, National Cancer Center, Korea, Nowon Eulji Medical Center, Pusan National University Hospital, Wonju Severance Christian Hospital, Inha University Hospital, Presbyterian medical center
Peptic Ulcer Hemorrhage
07/21
12/21
NORA, NCT04816838: A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations

Recruiting
N/A
25
RoW
Osimertinib
Yonsei University
Non Small Cell Lung Cancer
07/25
10/25
Im, Seock-Ah
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT04892693: Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Recruiting
2
70
RoW
Talazoparib Oral Capsule, Single arm; Talazoparib
Seoul National University Hospital
Advanced Breast Cancer
05/23
05/25
Post-CDK, NCT05536128: Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor

Not yet recruiting
2
64
RoW
Olaparib, (Lynparza Cap), Fulvestrant, Faslodex®
Seoul National University Hospital
Advanced Breast Cancer
12/23
12/25
 

Download Options